Onconase, a cytotoxic ribonuclease, in combination with standard of care agents in non-small cell lung tumorgraft models.

e13520 Background: Onconase is a cytotoxic amphibian ribonuclease of the RNAse A superfamily. It is currently being evaluated in phase I/II trials and has been shown to possess anti-tumor activity in many preclinical studies. In an effort to identify clinical indications for Onconase, non-small cell lung tumografts were treated with a combination of onconase and cisplatin or caboplatin-pemetrexed which currently constitute standard of care for this type of malignancy. Tumorgrafts are human solid tumors passed as heterogeneous whole-tumor fragments in immunocompromised mice and not cell line xenografts. Methods: Adenocarcinoma tumor graft models were treated pemetrexed 100 mg/kg, i.p. days 0-4, 7-11; carboplatin 60 mg/kg i.p. days 0, 7, 15; Onconase 5mg/kg i.v. days 0, 7, 14. Tumor volumes determined by caliper measurements. Tumor growth inhibition (TGI) was determined at study endpoint. Tumor samples were collected for further analysis of potential signatures of response by mutation and miRNA analysis. Re...